Hill Publishing Group | contact@hillpublisher.com

Hill Publishing Group

Location:Home / Journals / International Journal of Clinical and Experimental Medicine Research /

DOI:http://dx.doi.org/10.26855/ijcemr.2022.10.027

Successful Treatment of a COVID-19 Patient with Fulminant Myocarditis: A Case Report and Review of Literature

Date: November 25,2022 |Hits: 90 Download PDF How to cite this paper

Weicheng Wang1, Lingui Wang1, Jincheng Song2,*

1Department of Emergency, the Second Affiliated Hospital of Dalian Medical University, Dalian, China.

2Oncology Department, the Second Affiliated Hospital of Dalian Medical University, Dalian, China.

*Corresponding author: Jincheng Song

Abstract

Lung damage is the primary clinical concern when treating Coronavirus Disease 2019 (COVID-19) patients. However, not enough attention has been given to potential myocardial damage associated with COVID-19 infection. Here, we report a 65-year-old woman who diagnosed with COVID-19 and myocarditis based on 2019-nCoV nucleic acid test, electrocardiogram (ECG), and myocardial markers. The patient with fulminant myocarditis who presented with the following: (1) obvious symptoms of pulmonary infection without any cardiac-specific symptoms; (2) alleviation of pulmonary symptoms with worsening myocardial damage after treatment; and (3) sudden cardiac arrest caused by malignant arrhythmia. The patient was administered oral Ambroxol tablets, Arbidol Hydrochloride capsules, Lianhuaqingwen capsules (Traditional chinesemidicine), and Ibuprofen capsules, as well as intravenous Moxifloxacin, 20% human serum albumin, and Imipenem sildastatin sodium. On day 8 after hospitalization, the patient suddenly went into a cardiac arrest.After cardiopulmonary resuscitationand electric defibrillation, the patient's vital sign recovered and was immediately transferred to ICU for further treatment. The patient received high-dose methylprednisolone (500mg/d), immunoglobulin therapy (20g/d), ventilator-assisted ventilation, and extracorporeal membrane pulmonary oxygenation (ECMO).One month later, the patient was in stable condition and discharged home. This case study and the literature indicate that symptoms of myocardial injury caused by COVID-19 may be atypical and may develop prior to the onset of pulmonary symptoms. Therefore, active prevention and early adoption of various treatment measures, even in the absence of myocardial injury, may benefitCOVID-19 patients.

References

[1] Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19.  Int J Antimicrob Agents.2020;  55(5):105955. 

[2] Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al.  A pathological report of three COVID-19 cases by minimal invasive autopsies.  Zhonghua Bing Li Xue Za Zhi. 2020;  49(5):411-417. 

[3] Li JW, Han TW, Woodward M, Anderson CS, Zhou H, Chen YD, et al.  The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis [published online ahead of print, 2020 April 16].  Prog Cardiovasc Dis. 2020;  S0033-0620(20):30080-3. 

[4] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China [published online ahead of print, 2020 February 7].  JAMA.  2020;  323(11):1061-1069. 

[5] Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association.  Zhonghua Liu Xing Bing Xue Za Zhi. 2020;  41(2):139-144. 

[6] Wang D, Li S, Jiang J, Yan J, Zhao C, Wang Y, et al.  Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis.  Sci China Life Sci. 2019;  62(2):187-202. 

[7] Silva E, Montenegro JS, Estupiñán MC, Arias G, Osorio JP, Poveda CM, et al.  Fulminant myocarditis due to the influenza B virus in adults: Report of two cases and literature review.  Miocarditis fulminant eenadultosporel virus de la influenza B: reporte de dos casos y revisión de la literatura.  Biomedica. 2019;  39(Supl.  2):11-19. 

[8] Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al.  COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options [published online ahead of print, 2020 April 30].  Cardiovasc Res. 2020;  cvaa106. 

[9] Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin [pub-lished online ahead of print, 2020 March 16].  Eur Heart J. 2020;  ehaa190. 

[10] Kow CS, Hasan SS. Glucocorticoid versus immunoglobulin in the treatment of COVID-19-associated fulminant myocarditis [published online ahead of print, 2020 May 10].  Infection. 2020;1-2.  https://doi.org/10.1007/s15010-020-01441-4. 

[11] Lv J, Han B, Wang C, Wang J, Jiang D, Zhao L, et al.  The Clinical Features of Children With Acute Fulminant Myocarditis and the Diagnostic and Follow-Up Value of Cardiovascular Magnetic Resonance.  Front Pediatr. 2019;  7:388.  Published 2019 October 1. 

[12] Wei X, Fang Y, Hu H. Glucocorticoid and immunoglobulin to treat viral fulminant myocarditis.  Eur Heart J. 2020;  41(22):2122. 

[13] Leurent G, Langella B, Fougerou C, Lentz PA, Larralde A, Bedossa M, et al.  Diagnostic contributions of cardiac magnetic resonance imaging in patients presenting with elevated troponin, acute chest pain syndrome and unobstructed coronary arteries.  Arch Cardiovasc Dis. 2011;  104(3):161-170. 

[14] Mosebach CM, Tandon V, Kumar M. Acute Myocarditis Presenting as Acute Coronary Syndrome.  Cureus. 2019;  11(7):e5212.  Published 2019 July 23. 

[15] Punja M, Mark DG, McCoy JV, Javan R, Pines JM, Brady W. Electrocardiographic manifestations of cardiac infec-tious-inflammatory disorders.  Am J Emerg Med. 2010;  28(3):364-377. 

[16] Kang TD, Ren YL, Zhao H, Ning SQ and Liu WX.  Risk factors for adverse cardiac events in adults with fulminant myocarditis during hospitalization.  World J Clin Cases. 2020;  8(2):255-263. 

[17] Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al.  COVID-19 and Cardiovascular Disease.  Circula-tion.2020;  141(20):1648-1655. 

[18] Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A.Myocardial injury and COVID-19: Possible mechanisms.  Life Sci. 2020;  253:117723.

[19] Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents. 2020; 55(6):105982. 

[20] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 January 30]. Lancet. 2020; 395(10223):497-506. 

[21] Mahmud E, Dauerman HL, Welt FGP, Messenger JC, Rao SV, Grines C, et al. Management of Acute Myocardial Infarction During the COVID-19 Pandemic [published online ahead of print, 2020 April 21]. J Am Coll Cardiol. 2020; S0735-1097(20)35026-9. 

[22] Bassetti M, Giacobbe DR, Aliberti S, Barisione E, Centanni S, De Rosa FG, et al. Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Clin Microbiol Infect. 2020; 26(7):880-894. 

[23] ŞŞentürk M, El Tahan MR, Szegedi LL, Marczin N, Karzai W, Shelley B, et al. Thoracic Anesthesia of Patients With Suspected or Confirmed 2019 Novel Coronavirus Infection: Preliminary Recommendations for Airway Management by the European Association of Cardiothoracic Anaesthesiology Thoracic Subspecialty Committee [published online ahead of print, 2020 April 11]. J CardiothoracVascAnesth. 2020; S1053-0770(20)30309-8. 

[24] Rewa OG, Villeneuve PM, Lachance P, Eurich DT, Stelfox HT, Gibney RTN, et al. Quality indicators of continuous renal replacement therapy (CRRT) care in critically ill patients: a systematic review. Intensive Care Med. 2017; 43(6):750-763. 

[25] Chou HW, Wang CH, Lin LY, Chi NH, Chou NK, Yu HY, et al. Prognostic factors for heart recovery in adult patients with acute fulminant myocarditis and cardiogenic shock supported with extracorporeal membrane oxygenation. J Crit Care. 2020; 57:214-219.

How to cite this paper

Successful Treatment of a COVID-19 Patient with Fulminant Myocarditis: A Case Report and Review of Literature

How to cite this paper: Weicheng Wang, Lingui Wang, Jincheng Song. (2022) Successful Treatment of a COVID-19 Patient with Fulminant Myocarditis: A Case Report and Review of Literature. International Journal of Clinical and Experimental Medicine Research6(4), 489-496.

DOI: http://dx.doi.org/10.26855/ijcemr.2022.10.027

Volumes & Issues

Free HPG Newsletters

Add your e-mail address to receive free newsletters from Hill Publishing Group.

Contact us

Hill Publishing Group

8825 53rd Ave

Elmhurst, NY 11373, USA

E-mail: contact@hillpublisher.com

Copyright © 2019 Hill Publishing Group Inc. All Rights Reserved.